Rare forms of congenital hyperinsulinism

Area of Science:

• Genetics
• Endocrinology
• Metabolic Disorders

Background:

• Rare congenital hyperinsulinism (CHI) presents with diverse clinical features and genetic causes.
• Mutations in genes like GLUD1, GCK, HADH, SLC16A1, HNF4A, and UCP2 are implicated in rare CHI forms.
• Heterogeneity in onset, severity, symptoms, and treatment response necessitates personalized patient care.

Purpose of the Study:

• To review the genetic basis of rare congenital hyperinsulinism (CHI) forms.
• To discuss the heterogeneous clinical presentations and diagnostic challenges.
• To outline current and alternative treatment strategies for rare CHI.

Main Methods:

• Literature review of genetic mutations causing rare CHI.
• Analysis of clinical heterogeneity and treatment responses.
• Evaluation of pharmacological and surgical management options.

Main Results:

• Specific gene mutations (GLUD1, GCK, HADH, SLC16A1, HNF4A, UCP2) are identified in rare CHI.
• Diazoxide is a first-line treatment but shows variable efficacy, especially in GCK and SLC16A1 defects.
• Octreotide serves as a second-line option, and pancreatectomy is reserved for refractory cases.

Conclusions:

• Individualized diagnosis and treatment are crucial for rare CHI patients.
• Management requires expert multidisciplinary teams at specialized centers.
• Optimizing treatment involves careful consideration of drug efficacy, side effects, and surgical options.